Top plastic surgeons slam the brakes on teen gender surgeries—mastectomies, vaginoplasties, and more—until age 19. Why? Hidden infertility bombs, regret epidemics, and crumbling evidence. As states ban and Trump’s HHS cheers, what explosive secrets are finally unraveling? Parents, brace yourselves.
The American Society of Plastic Surgeons (ASPS), representing over 11,000 U.S. specialists, issued a position statement on February 3, 2026, recommending that plastic surgeons delay gender-related surgeries—such as breast/chest, genital, and facial procedures—for individuals under 19 years old. This guidance cites insufficient evidence of benefits outweighing risks for minors, amid growing scrutiny of gender-affirming care.
The ASPS Recommendation Explained
ASPS’s statement emphasizes a “precautionary approach” due to low-certainty evidence on long-term outcomes for pediatric gender dysphoria treatments. It applies to irreversible surgeries in a population where distress may resolve naturally, with studies showing many prepubertal cases improving without intervention. The society stresses ethical principles like beneficence and non-maleficence, noting surgeons’ independent duty to assess risks beyond referrals.
From a U.S. viewpoint, this aligns with federal shifts under President Trump’s administration. HHS Secretary Robert F. Kennedy Jr. praised ASPS for prioritizing “sound science” over “overmedicalization,” amid proposed rules barring federal funding for such care in minors.
Why Evidence Falls Short
Systematic reviews underpin ASPS’s caution. The 2024 Cass Review (UK), 2025 HHS report, and a 2025 meta-analysis in Plastic and Reconstructive Surgery found very low/low certainty for mental health benefits from surgeries or hormones in youth under 26. Complications like infertility, sexual dysfunction, and bone density loss are documented, but positive outcomes lack robust, long-term data.
Many U.S. guidelines (WPATH, Endocrine Society, AAP) fail methodological standards for trustworthiness, per Cass appraisals—issues include poor conflict management and weak evidence links. ASPS notes adolescent brains aren’t fully mature for irreversible choices, with no reliable predictors of persistent dysphoria.
| Evidence Aspect | Certainty Level | Key Concerns |
| Mental Health Outcomes | Very Low/Low | No clear causal benefit; confounding from prior hormones/therapy |
| Long-Term Physical Harms | Low/Moderate | Fertility loss, osteoporosis, sexual function issues |
| Natural Resolution Rates | Moderate | High in prepubertal onset (60-90% desist); adolescent data limited |
| Suicide Risk Reduction | Very Low | Rare baseline; no proven surgery impact |
- The Great American “Lock In”: Why the 2025 Winter Arc is the Only Resolution That Actually Works (If You Don’t Make This Fatal Mistake)
- 3 Midlife Habits Linked to Almost 13 More Dementia-Free Years, According to a 26-Year Study of 12,409 Adults
- 37% of Women Over 65 Are Losing Hair — But the Real Shocker Is How Many Younger Women Are Now Using These FDA-Approved At-Home Treatments to Stop It Early
- 40% of US Adults at Risk: Experts Break Down Fatty Liver Surge, Hidden Gut Issues, and Simple Steps to Protect Your Liver Now
- 5 Simple Home Tests to Check If Your Eggs Are Still Safe to Eat Past the Expiration Date
- 5 Subtle Eye Symptoms Warning of Kidney Problems US Adults Should Never Ignore
Broader U.S. Policy Landscape
Twenty-six states now restrict gender-affirming care for minors, often classifying violations as felonies with penalties up to 10 years. Federal proposals from CMS would exclude hospitals offering these from Medicare/Medicaid, echoing HHS’s 2025 pediatric dysphoria review. The Supreme Court upheld Tennessee’s ban in 2025, signalling judicial support for caution.
Internationally, Finland, Sweden, and the UK limit such interventions to research or adulthood, influencing U.S. debates. ASPS opposes criminalization, favouring professional self-regulation.
Rarity of Surgeries in Minors
Data shows gender surgeries on U.S. minors are uncommon. A 2019-2023 analysis found none under 13, with top surgeries rare even at 16-17; bottom surgeries almost never before 18. WPATH requires persistent dysphoria diagnosis, therapy, and informed consent—yet ASPS argues these don’t suffice amid evidence gaps.
This rarity tempers fears of overuse but highlights why ASPS focuses on evidence thresholds for the few cases.
Balancing Care and Caution
ASPS affirms patient dignity for all, including detransitioners, without endorsing specific paths. It urges multidisciplinary input, thorough consent assessing developmental capacity, and awareness of prior interventions’ impacts (e.g., puberty blockers on cognition). Critics like AAP oppose restrictions, citing distress relief needs, but ASPS prioritizes verifiable benefits.
For U.S. families, this means exploring therapy first—evidence shows many youth navigate dysphoria without medicalization. President Trump’s HHS pushes “biological truth,” potentially reshaping access nationwide.
Long-Term risks of Gender Surgeries in Adolescents
Gender-affirming surgeries in adolescents carry significant long-term risks, though high-quality data is limited due to short follow-up periods and rarity of procedures in minors. Systematic reviews like the Cass Review and ASPS analyses rate evidence as low certainty, highlighting irreversible harms without proven mental health benefits.
Physical Risks
Common long-term complications include infertility from gonad removal, sexual dysfunction (e.g., painful intercourse, reduced sensation), urinary issues (incontinence, strictures), and neovagina prolapse or stenosis requiring lifelong dilation. Facial surgeries risk chronic pain or asymmetry; chest surgeries may cause poor healing or necrosis. Bone density loss and cardiovascular strain often stem from prior puberty blockers, exacerbating surgery outcomes.
Mental Health and Regret
Long-term studies show no lasting psychological improvements; Swedish 40-year data post-surgery indicates 19x higher suicide rates vs. general population. Detransition rates reach 30% in some analyses, with regret involving permanent loss of function (e.g., no breast reconstruction post-mastectomy). Adolescent brain immaturity heightens poor decision-making risks.
Evidence Gaps
Every systematic review (Cass, Finnish, Swedish) finds uncertain benefits and probable net harms, including sterility and fertility loss. ASPS cites “low quality/low certainty” for efficacy in youth.
| Risk Category | Examples | Certainty/Evidence |
| Reproductive | Infertility, sterility | High (expected from gonadectomy) |
| Sexual Function | Dyspareunia, loss of orgasm | Moderate (common reports) |
| Urinary | Fistulas, UTIs, stenosis | Moderate (surgical data) |
| Skeletal/Cardio | Osteoporosis, CVD | Low (from blockers + hormones) |
| Psychological | Persistent suicidality, regret | Low (long-term cohorts) |
Implications for Patients and Providers
Minors and parents face heightened scrutiny in informed consent, with surgeons documenting uncertainties like evolving identity or desistance risks. Providers in restrictive states must track policies; ASPS advises legal counsel. Detransition stories underscore irreversibility—lost breast tissue or function can’t be undone.
Ethically, ASPS distinguishes gender surgeries from other adolescent plastics (e.g., gynecomastia): the former hinge on unproven persistence predictions and psych benefits. Delay to 19 allows maturity without denying adult access.
Road Ahead: Evidence Over Ideology
The American Society of Plastic Surgeons (ASPS) pledges to promptly revise its guidelines should robust, long-term randomized controlled trials or high-certainty cohort studies emerge, clearly demonstrating that benefits of gender-related surgeries—such as mastectomies, vaginoplasties, or phalloplasties—outweigh risks like infertility, sexual dysfunction, and regret in adolescents.
ASPS actively champions rigorous, independent research to address critical evidence gaps, including desistance rates, brain maturity impacts, and post-surgical mental health outcomes. This commitment persists despite intensifying U.S. politicization, where debates pit child protection advocates against those prioritizing immediate access to alleviate dysphoria.
This evidence-driven stance exemplifies principles in medicine—Experience from 11,000+ surgeons, Expertise via systematic reviews like Cass, Authoritativeness as the leading U.S. plastic surgery body, and Trustworthiness through transparency. It elevates patient welfare above ideological trends or short-term pressures.
For families, providers, and policymakers in 2026, ASPS’s approach offers a beacon: science, not sentiment, must guide irreversible decisions affecting youth. As HHS advances federal restrictions and states enforce bans, expect accelerated studies to shape tomorrow’s standards—potentially confirming caution or unlocking safer paths forward. Ongoing multidisciplinary collaboration, free from conflicts, remains essential to resolve this pivotal tension.
Omisha is a health writer passionate about turning complex medical research into clear, actionable content readers can trust. She covers everything from nutrition and mental wellness to chronic disease management, always grounding her work in credible science and real-world relevance. When she's not writing, she's usually reading up on the latest health studies or exploring new wellness trends to write about next.
